Cargando…
Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer
c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363986/ https://www.ncbi.nlm.nih.gov/pubmed/11742498 http://dx.doi.org/10.1054/bjoc.2001.2139 |
_version_ | 1782153841659084800 |
---|---|
author | McPhillips, F Mullen, P Monia, B P Ritchie, A A Dorr, F A Smyth, J F Langdon, S P |
author_facet | McPhillips, F Mullen, P Monia, B P Ritchie, A A Dorr, F A Smyth, J F Langdon, S P |
author_sort | McPhillips, F |
collection | PubMed |
description | c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G (2)/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease. © 2001 Cancer Research Campaign http://www.bjcancer.com |
format | Text |
id | pubmed-2363986 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2001 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23639862009-09-10 Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer McPhillips, F Mullen, P Monia, B P Ritchie, A A Dorr, F A Smyth, J F Langdon, S P Br J Cancer Regular Article c-Raf is an essential component of the extracellular related kinase (ERK) signal transduction pathway. Immunohistochemical staining indicated that c-Raf was present in 49/53 ovarian adenocarcinomas investigated and high c-Raf expression correlated significantly with poor survival (P = 0.002). c-Raf protein was detected in 15 ovarian cancer cell lines. Antisense oligodeoxynucleotides (ODNs) (ISIS 5132 and ISIS 13650) reduced c-Raf protein levels and inhibited cell proliferation in vitro. Selectivity was demonstrated by the lack of effect of ISIS 5132 on A-Raf or ERK, while a random ODN produced only minor effects on growth and did not influence c-Raf expression. ISIS 5132 produced enhanced apoptosis and cells accumulated in S and G (2)/M phases of the cell cycle. In vivo, ISIS 5132 inhibited growth of the s.c. SKOV-3 xenograft while a mismatch ODN had no effect. These data indicate that high levels of c-Raf expression may be important in ovarian cancer and use of antisense ODNs targeted to c-Raf could provide a strategy for the treatment of this disease. © 2001 Cancer Research Campaign http://www.bjcancer.com Nature Publishing Group 2001-11 /pmc/articles/PMC2363986/ /pubmed/11742498 http://dx.doi.org/10.1054/bjoc.2001.2139 Text en Copyright © 2001 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Regular Article McPhillips, F Mullen, P Monia, B P Ritchie, A A Dorr, F A Smyth, J F Langdon, S P Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title_full | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title_fullStr | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title_full_unstemmed | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title_short | Association of c-Raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
title_sort | association of c-raf expression with survival and its targeting with antisense oligonucleotides in ovarian cancer |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363986/ https://www.ncbi.nlm.nih.gov/pubmed/11742498 http://dx.doi.org/10.1054/bjoc.2001.2139 |
work_keys_str_mv | AT mcphillipsf associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT mullenp associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT moniabp associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT ritchieaa associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT dorrfa associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT smythjf associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer AT langdonsp associationofcrafexpressionwithsurvivalanditstargetingwithantisenseoligonucleotidesinovariancancer |